Huntington's Disease Screening in Outpatient Neurology
GIA® screens during rooming or in the waiting area before the neurologist enters — capturing structured cognitive, motor-speech, and behavioral biomarker data that the specialist reviews alongside the patient's history and exam. The 40-second conversation produces results in under two minutes, available in the EHR before the face-to-face portion of the visit begins.
Huntington’s disease is a rare, autosomal-dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene. The meta-analytic worldwide prevalence is 2.71 per 100,000 (95% CI 1.55–4.72), rising to 5.70 per 100,000 (95% CI 4.42–7.35) in Europe, North America, and Australia and falling to 0.40 per 100,000 in Asia (Pringsheim et al., Movement Disorders 2012; meta-analysis of 13 prevalence studies). The Huntington’s Disease Society of America (HDSA) estimates approximately 41,000 symptomatic Americans and over 200,000 individuals at risk for inheriting the gene. Disease expression follows a recognizable trajectory: motor signs (chorea, bradykinesia, dystonia), cognitive change (executive dysfunction, processing speed), and psychiatric manifestations (depression, irritability, apathy). Speech and motor-speech changes are documented in both manifest and premanifest carriers, often years before clinical motor onset crosses diagnostic threshold. Peer-reviewed research from a Beth Israel Deaconess Medical Center, UC San Diego School of Medicine, and Harvard Medical School collaboration demonstrates that speech-based deep neural networks can model Huntington’s disease progression before clinical symptoms appear — supporting longitudinal tracking through the premanifest and early-manifest phases.
Outpatient neurology evaluates and manages cognitive, movement, and neurodegenerative disorders referred from primary care or self-referred. Among Medicare patients referred for neurology evaluation, the average wait to first appointment is 34 days, and 18% wait longer than 90 days (AAN study, Neurology, 2025). The underlying peer-reviewed speech biomarker research reports AUC 0.97 for Parkinson's disease detection from natural conversation (Sensitivity 0.98, Specificity 0.96). GIA® delivers that structured speech-biomarker data during the encounter itself — available in the EHR before the neurologist begins the face-to-face portion of the visit.
Why Huntington's Disease goes undetected in outpatient neurology
A neurologist or neurology nurse practitioner conducts the patient encounter. Support staff (medical assistants or clinical staff) handle intake and vitals. Comprehensive cognitive and neurological screening competes with the chief complaint, history, exam, and care planning within the visit length. Huntington's Disease symptoms are often subtle, progressive, and easily attributed to other factors in this care environment.
Among Medicare patients referred for neurology evaluation, 18% wait longer than 90 days for their first appointment (average wait: 34 days; AAN study, Neurology, 2025) — primary-care referrers operate without longitudinal data on the referred patient until the visit occurs
New-patient outpatient neurology visits run 45-59 minutes (CPT 99204) or 60-74 minutes (CPT 99205); history-taking, neurological and cognitive exam, differential diagnosis, care planning, and patient education compete for the same time window
Established-patient follow-up visits at 30-39 minutes (CPT 99214) or 40-54 minutes (CPT 99215) at a 3, 6, or 12-month cadence miss interval cognitive or motor-speech changes that would inform medication titration or care-plan decisions
Formal neuropsychological testing (CPT 96132 first hour + 96133 each additional hour) is administered in a separate extended-time encounter when comprehensive cognitive characterization is warranted — adding to total time-to-evaluation across the diagnostic pathway
How does GIA® screen for Huntington's Disease in outpatient neurology?
GIA® meets the patient by video, voice, or landline — wherever they are in the outpatient neurology environment. The screening conversation takes 40 seconds and feels like a natural check-in, not a clinical assessment.
During the conversation, GIA® analyzes over 2,500 speech biomarkers — including vocal tremor, articulatory precision, prosodic patterns, and cognitive load indicators — alongside 436 visual data points from facial micro-expressions and body movement during video sessions.
Results are delivered to the clinician in under 2 minutes. Four data types write back to the EHR automatically: structured screening results with ICD-10 codes, clinician-ready medical notes, a full timestamped transcript, and the recorded patient video. The clinician reviews and submits — the human is always in the loop.
Huntington's Disease in outpatient neurology: the numbers.
The screening challenge
A new-patient neurology evaluation must combine history, neurological and cognitive exam, differential diagnosis, care planning, and patient education within 45-59 minutes (CPT 99204) or 60-74 minutes (CPT 99205). Formal neuropsychological testing (CPT 96132 first hour + 96133 each additional hour) is administered in a separate extended-time encounter when comprehensive cognitive characterization is warranted — it is not part of the new-patient encounter. Between scheduled visits, the specialist depends on patient self-report or primary-care follow-up, losing interval signal on progression that would inform medication titration or care-plan decisions. GIA® supplies structured cognitive and motor-speech biomarker data without consuming clinician visit time. Documentation supports billing accuracy for E/M coding; coding decisions remain with the clinical documentation and coding team.
What compliance requirements does this address?
E/M visit coding for outpatient services: CPT 99204 (45-59 min) / 99205 (60-74 min) for new patients; CPT 99214 (30-39 min) / 99215 (40-54 min) for established patients (AMA CPT 2026; CMS MLN006764). CPT 96132 (first hour) and 96133 (each additional hour) cover neuropsychological testing evaluation services when comprehensive cognitive characterization is clinically indicated. Documentation supports billing accuracy and the documented level of medical decision-making; coding decisions remain with the clinical documentation and coding team.
GIA® produces structured documentation automatically — screening results with ICD-10 codes, clinician-ready medical notes, full timestamped transcripts, and recorded patient video — all written back to the EHR in real time and available for clinical, billing, and compliance review.
Huntington's Disease screening in outpatient neurology
How is Huntington's Disease screened in outpatient neurology?
GIA® screens for Huntington's Disease through a single conversational interaction lasting 40 seconds. She analyzes over 2,500 speech biomarkers using Voice AI, Computer Vision, and Speech Biomarkers. GIA® screens during rooming or in the waiting area before the neurologist enters — capturing structured cognitive, motor-speech, and behavioral biomarker data that the specialist reviews alongside the patient's history and exam. The 40-second conversation produces results in under two minutes, available in the EHR before the face-to-face portion of the visit begins. Results are delivered to the clinician in under 2 minutes.
Does Huntington's Disease screening require additional staff?
No. GIA® conducts the screening conversation independently — zero additional clinical staff required during the interaction. A neurologist or neurology nurse practitioner conducts the patient encounter. Support staff (medical assistants or clinical staff) handle intake and vitals. Comprehensive cognitive and neurological screening competes with the chief complaint, history, exam, and care planning within the visit length. The clinician reviews the results in under 2 minutes.
What is the accuracy of Huntington's Disease screening?
Huntington's Disease screening accuracy: Clinically validated vocal biomarker screening. The platform is peer-reviewed across 19 published studies and trained on 12.3 million longitudinal PAC/LTC patient records and 27 billion clinical events.
How does GIA® fit into the neurology visit workflow?
GIA® screens during rooming or in the waiting area before the neurologist enters. The 40-second conversation produces structured cognitive, motor-speech, and behavioral biomarker results in under two minutes — available in the EHR for the neurologist to review alongside the patient's history and exam during the face-to-face encounter.
How does GIA® support documentation for outpatient E/M coding (99204 / 99205 / 99214 / 99215)?
GIA® writes structured screening results with ICD-10 codes, clinician-ready medical notes, a full timestamped transcript, and the recorded patient video back to the EHR in real time. That documentation contributes to the level of medical decision-making documented in support of E/M coding (99204 / 99205 for new patients; 99214 / 99215 for established patients). Documentation supports billing accuracy; coding decisions remain with the clinical documentation and coding team.
Can GIA® be used between scheduled neurology visits to monitor progression?
Yes. GIA® can be administered by phone, landline, or video between scheduled visits — capturing interval changes in speech biomarkers that signal cognitive or motor-speech progression. Results write back to the EHR for clinician review at the next visit, or asynchronously if the change is clinically significant.
How does GIA® relate to formal neuropsychological testing (CPT 96132 / 96133)?
GIA® is a screening tool, not a neuropsychological battery. It surfaces structured risk signals from speech and behavioral biomarkers in 40 seconds. Formal neuropsychological evaluation (CPT 96132 first hour + 96133 each additional hour) remains the appropriate next step when GIA® or other screening evidence warrants comprehensive cognitive characterization. The clinician determines when formal testing is indicated.
How does GIA® screen for Huntington’s disease?
GIA® analyzes 2,500+ speech biomarkers — including articulation rate, vocal stability, prosodic patterns, processing-speed markers, and motor-speech signatures associated with Huntington’s disease — from a natural conversation lasting 40 seconds. Results write back to the EHR with structured notes for clinician review. A clinician reviews and approves every result before it enters the clinical record. Peer-reviewed research demonstrates that speech-based deep neural networks can model Huntington’s disease progression before clinical symptoms appear (Beth Israel Deaconess Medical Center / UC San Diego / Harvard Medical School collaboration).
Why is premanifest detection of Huntington’s disease clinically important?
CAG-positive carriers experience subtle prodromal changes in cognition, motor speech, and psychiatric profile years — sometimes decades — before motor onset crosses formal diagnostic threshold. The premanifest period is the operative window for emerging disease-modifying therapies in active clinical development, for individualized care planning, for family-planning conversations, and for treatment-response monitoring. Speech biomarker tracking offers a non-invasive, repeatable measurement of this window without requiring formal motor-symptom progression.
Does GIA® diagnose Huntington’s disease?
No. GIA® screens — she does not diagnose. Symptomatic Huntington’s disease is diagnosed clinically by a neurologist or movement-disorder specialist and confirmed genetically by HTT CAG-repeat testing. GIA® surfaces structured risk signals from speech biomarker analysis for clinician review; the clinician determines when genetic counseling and confirmatory testing are indicated. GIA® is a clinical decision support tool with mandatory clinician-in-the-loop review on every result.
How does GIA® support longitudinal Huntington’s tracking between specialist visits?
GIA® can be administered by phone, landline, or video between scheduled neurology or movement-disorder visits — capturing interval changes in speech biomarkers that signal progression along the premanifest-to-manifest trajectory. Results write back to the EHR for clinician review at the next visit, or asynchronously if the change is clinically significant. The same 40-second conversation captures cognitive, motor-speech, and psychiatric biomarker signals across the multi-domain Huntington’s presentation in a single screening.
How does GIA® relate to the Unified Huntington’s Disease Rating Scale (UHDRS)?
The UHDRS remains the standard structured assessment for clinical Huntington’s disease characterization. It requires trained administration and takes 30 to 45 minutes per patient, which limits between-visit measurement frequency outside specialty centers and clinical-trial sites. GIA® is a screening and longitudinal-tracking tool, not a replacement for the UHDRS. GIA® surfaces structured speech biomarker signals from a 40-second conversation, which can be administered more frequently and asynchronously, supporting longitudinal tracking between formal UHDRS assessments rather than substituting for them.
Huntington's Disease screening in other care settings
Other conditions screened in outpatient neurology
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.
See GIA® screen for Huntington's Disease live
40 seconds. 60-second results. Zero staff time.